Genmab — December 2016
-
-
Godt indslag, Helge. At kursen ligger her på samme niveau som medio maj forstår jeg nok ikke helt. Investorererne kan umuligt have indregnet samtlige gode nyheder og godkendelser og den hastighed de er kommet. Forklaringen kan kun ligge i makro - bad standing i branchen, økonomisk og politisk uro som lægger pres på hele aktiemarkedet 2016. Håber '
17 bliver lidt bedre;-) -
Rigtig godt indslag Helge. Måske vi skulle få det tekstet (engelsk)
og lagt på youtube
-
Nogen der har en ide om, hvem der sælger ud af Genmap nu?
-
Ja verden er a lave
-
Ja Bulder, det siger Novod også "The overall response rate for Dara subcutaneous 1,800 mg was 38% and also included deep responses (versus the 31% ORR in the monotherapy IV indication for Dara). The trials are distinctly different and we cannot compare across trials and settings, but as noted above, the data is intriguing."
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind